Nomura Holdings
BCRX icon

Nomura Holdings’s BioCryst Pharmaceuticals BCRX Stock Holding History

Nomura Holdings’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,328,291
Closed -$15.2M – 1457
2022
Q4 		$15.2M Buy
1,328,291
+1,044,484
+368% +$13M 0.06% 228
2022
Q3 		$3.57M Buy
+283,807
New +$3.65M 0.01% 654
2014
Q2 		– Sell
-13,448
Closed -$142K – 2744
2014
Q1 		$142K Buy
+13,448
New +$143K ﹤0.01% 2433
2013
Q4 		– Sell
-92,836
Closed -$677K – 1998
2013
Q3 		$677K Buy
92,836
+74,884
+417% +$380K ﹤0.01% 1241
2013
Q2 		$28K Buy
+17,952
New +$31K ﹤0.01% 2119

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Nomura Holdings's BCRX Position: Q1 2023 in Review

Nomura Holdings sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2023, closing a stake of 1,328,291 shares — an estimated $15.2M sold.

Nomura Holdings first reported a position in BCRX in Q2 2013 and held it in 5 quarters. The position peaked at $15.2M in Q4 2022. 240 funds tracked by Wall St. Rank hold BCRX as of Q1 2023.

  • Nomura Holdings reported no remaining BioCryst Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Nomura Holdings sold 1,328,291 BioCryst Pharmaceuticals shares in Q1 2023, an estimated $15.2M.
  • Nomura Holdings first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Nomura Holdings's BioCryst Pharmaceuticals position peaked at $15.2M in Q4 2022.
  • 240 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2023.

Based on Nomura Holdings's 13F filing for Q1 2023, filed 15 May 2023.